Literature DB >> 2077175

Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart.

N Tanaka1, T Nozawa, Y Yasumura, S Futaki, K Hiramori, H Suga.   

Abstract

We studied whether there is an optimal heart rate (HR) that would minimize myocardial oxygen consumption (MVO2) per min for a constant minute cardiac work. We measured minute MVO2 (ml O2/min) of the left ventricle paced at increasing rates (100-200 beats/min) in 10 right-heart-bypassed dogs. In each experiment, cardiac output was kept constant with a constant-flow bypass pump, and mean aortic pressure was also kept constant by inflation or deflation of an intra-aortic balloon. Minute cardiac work was thus kept constant. Minute MVO2 was obtained as the product of mean coronary arteriovenous O2 difference and mean coronary blood flow drained from the collapsed right ventricle. Both left ventricular Emax (contractility index defined as the slope of the left ventricular end-systolic pressure-volume relation) and PVA (pressure-volume area as a measure of total mechanical energy of contraction) were obtained by an abrupt aortic occlusion method. The obtained-minute MVO2-HR relationship showed a good linear positive correlation (r = 0.824-0.995) in every heart. We accounted for this relationship by the changes in PVA and Emax that we had proposed as primary determinants of MVO2. We conclude that minute MVO2 for a constant minute cardiac work increased monotonically with increases in HR from 100 to 200 beats/min, being minimum at the lowest HR, and that this relation was ascribable to the HR-proportional increase in the MVO2 component for the excitation-contraction coupling.

Entities:  

Mesh:

Year:  1990        PMID: 2077175     DOI: 10.2170/jjphysiol.40.503

Source DB:  PubMed          Journal:  Jpn J Physiol        ISSN: 0021-521X


  14 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 2.  Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.

Authors:  John R Kapoor; Paul A Heidenreich
Journal:  Curr Heart Fail Rep       Date:  2012-06

3.  Heart rate in coronary artery disease: should we lower it?

Authors:  Kelly Axsom; Sripal Bangalore
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

Review 4.  The effects of heart rate control in chronic heart failure with reduced ejection fraction.

Authors:  Dario Grande; Massimo Iacoviello; Nadia Aspromonte
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

Review 5.  'Autonomic conflict': a different way to die during cold water immersion?

Authors:  Michael J Shattock; Michael J Tipton
Journal:  J Physiol       Date:  2012-04-30       Impact factor: 5.182

Review 6.  Ivabradine: potential clinical applications in critically ill patients.

Authors:  Vincenzo De Santis; Domenico Vitale; Anna Santoro; Aurora Magliocca; Andrea Giuseppe Porto; Cecilia Nencini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2012-10-14       Impact factor: 5.460

Review 7.  Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.

Authors:  G Heusch
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 8.  Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.

Authors:  Gerd Heusch; Petra Kleinbongard
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

9.  Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine.

Authors:  Takeshi Kitai; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

10.  Prognostic value of admission heart rate in patients with ST-segment elevation myocardial infarction: role of type 2 diabetes mellitus.

Authors:  Zhang Han; Yang Yan-min; Zhu Jun; Liu Li-sheng; Tan Hui-qiong; Liu Yao
Journal:  BMC Cardiovasc Disord       Date:  2012-11-15       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.